Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q3 FY23 results · Oct–Dec 2022
Natco Pharma reported revenue from operations of ₹492.50 crore (down 12.1% from Q3 FY22) and net profit of ₹62.30 crore (down 22.5% from Q3 FY22) for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 492.50 | 560.50 | −12.1% | 432.10 | +14.0% |
| Other income | 20.80 | 30.20 | −31.1% | 20.50 | +1.5% |
| Total income | 513.30 | 590.70 | −13.1% | 452.60 | +13.4% |
| Profit before tax | 81.40 | 91.00 | −10.5% | 70.30 | +15.8% |
| Net profit for the period | 62.30 | 80.40 | −22.5% | 56.80 | +9.7% |
| EPS, basic (₹) | 3.41 | 4.41 | −22.7% | 3.11 | +9.6% |
| Net margin (%) | 12.6 | 14.3 | 13.1 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 413.00 | 529.50 | −22.0% | 351.10 | +17.6% |
| Other income | 18.60 | 31.60 | −41.1% | 16.20 | +14.8% |
| Total income | 431.60 | 561.10 | −23.1% | 367.30 | +17.5% |
| Profit before tax | 45.00 | 79.70 | −43.5% | 46.30 | −2.8% |
| Net profit for the period | 37.30 | 71.60 | −47.9% | 37.70 | −1.1% |
| EPS, basic (₹) | 2.04 | 3.93 | −48.1% | 2.07 | −1.4% |
| Net margin (%) | 9.0 | 13.5 | 10.7 |
Consolidated
- Filed with BSE
- 09 Feb 2023, 16:57 IST
- Board meeting
- 09 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Feb 2023, 16:57 IST
- Board meeting
- 09 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE